|
Stavudine
resources
|
|
|
|
|
|
DRUG INFO
Stavudine
Drug Name:
Stavudine
Indication: For the treatment of human immunovirus (HIV) infections
Pharmacology: Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.
Mechanism Of Action: Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.
Drug Category: Anti-HIV Agents; Antimetabolites; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; ATC:J05AF04
Brand Names/Synonyms: D4T; D4T & GM-CSF; DHT; DRG-0043; Ddethd; Ddetyd; Estavudina [Inn-Spanish]; STAVUDINE; STV; Sanilvudine; Stavudine; Stavudine [Usan:Ban:Inn]; Stavudinum [Inn-Latin]; Zerit; Zerit Xr; Zerut Xr
Dosage Forms: CAPSULE
Absorption: Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%)
Interactions:
DrugBank: Interactions for Stavudine
Interactions for Stavudine:
: Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. Therefore,
use of zidovudine in combination with ZERIT should be avoided.
In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant
concentrations by doxorubicin and ribavirin. The clinical significance of these in vitro interactions is
unknown; therefore, concomitant use of stavudine with either of these drugs should be undertaken with caution.
Chemical IUPAC Name: 1-[5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione
Chemical Formula: C10H12N2O4
Half Life: 0.8-1.5 hours (in adults)
Drug Type: Approved Drug
# Accession No: APRD00440
CAS Registry Number: 3056-17-5
|
|
|
|
|
|
Stavudine News
(When available)
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 13, 2006
Cancer Consultants (press release), Reference: Ferrajoli A, O’Brien SM, Faderl SH et al. Rituximab plus GM-CSF for Patients with Chronic Lymphocytic Leukemia. Blood. ...
Rituxan® Plus GM-CSF Safe and Effective for Chronic Lymphocytic ... Jan 12, 2006
Cancer Consultants (press release), Reference: Ferrajoli A, O’Brien SM, Faderl SH, et al. Rituximab plus GM-CSF for patients with chronic lymphocytic leukemia. Blood . ...
Berlex Oncology Introduces New Formulation of Leukine With ... Jan 10, 2006
PharmaLive.com (press release), ...a unit of Berlex Laboratories, a US affiliate of Schering AG, Germany , today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R ...
Berlex Oncology Introduces New Formulation of Leukine(R) With ... Jan 10, 2006
PR Newswire (press release), Laboratories, a US affiliate of Schering AG, Germany (NYSE: SHR) , today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R ...
BiovaxID, Personalized Anti-Cancer Vaccine from Biovest ... Jan 10, 2006
PharmaLive.com (press release), BiovaxID is comprised of tumor-derived Id protein (tumor antigen) conjugated to KLH as a carrier protein administered with GM-CSF (granulocyte macrophage ...
Berlex Oncology Introduces New Formulation of Leukine(R) With ... Jan 10, 2006
PR Newswire (press release), ...a US affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), today announced its granulocyte macrophage colony stimulating factor (GM-CSF) LEUKINE(R ...
Zenotech to launch two bio generics in Feb, plans GDR Dec 20, 2005
Newindpress, The two products - recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and recombinant human granulocyte colony stimulating factor (G ...
‘Transfusion not necessary’ Dec 18, 2005
Trinidad News, Among the other alternatives to blood transfusions are G-CSF (granulocyte colony stimulating factor) and GM-CSF (granulocyte macrophage colony stimulating ...
Synta Pharmaceuticals to Focus 2006 Development on Its Oral IL-12 ... Dec 23, 2005
Yahoo! News (press release) ...of pro-inflammatory Th1 cytokines active in psoriasis, such as IL-23, and increased levels of Th2 and anti-inflammatory cytokines, such as IL-10 and GM-CSF. ...
Taxane-Based Breast Cancer Treatment Cost-Effective Compared to 5 ... Dec 13, 2005
DG News ..."Most clinicians, in order to prevent bouts of febrile neutropenia would add GM-CSF [granulocyte monocyte colony stimulating factor]," she said. ...
ASH: Rituxan-Vaccine Combo Boosts NHL Response Rates Dec 13, 2005
MedPage Today, ...then went on to receive the FavId vaccinations in a dose of 1 mg delivered subcutaneously monthly for six months, starting on week 12, with GM-CSF at 250 mcg ...
Cell Genesys Reports Positive Results from Phase 2 Trial of GVAX ... Dec 12, 2005
DG News The vaccines are comprised of tumor cells that have been genetically modified to secrete GM-CSF, an immune stimulatory hormone that plays a key role in ...
ICAAC: Switch from AZT or d4T to tenofovir may improve blood fat ... Jan 13, 2006
Aidsmap, Patients switching from anti-HIV drug regimens containing AZT (zidovudine, Retrovir) or d4T (stavudine, Zerit) may show better improvements in blood fat levels ...
Switching from AZT results in only slight reversal of lipoatrophy Dec 30, 2005
The Advocate, ...com reports. Switching from Zerit (d4T) to Viread or Ziagen posted much better gains in limb fat, according to the study. The researchers ...
ICAAC: Nevirapine’s manufacturer examines rates of liver ... Jan 9, 2006
Aidsmap, ...and nevirapine. All of the patients took a background combination of 3TC (lamivudine, Epivir) and d4T (stavudine, Zerit). Although ...
FDA Tentatively OKs Generic AIDS Drug Dec 21, 2005
Leading The Charge, Stavudine for oral solution is the first generic version of the previously approved Zerit for oral solution manufactured by Bristol-Myers Squibb. ...
Aurobindo gets USFDA nod for Stavudine Solution Dec 22, 2005
Business Standard, Stavudine oral solution 1 mg/ml is the first generic version approval of Zerit oral solution manufactured by Bristol-Myers Squibb. ...
Aurobindo oral solution gets FDA nod Dec 23, 2005
Business Standard, The company has added that Stavudine Oral Solution 1 mg/ml is the first generic version approval of Zerit for Oral Solution manufactured by Bristol-Myers Squibb ...
Aurobindo gets USFDA approval for Stavudine Dec 23, 2005
Sify, The company stated that Stavudine Oral Solution is the first generic version approval of Zerit for Oral solution manufactured by BristolMyers Squibb. ...
FDA Tentatively Approves a Generic AIDS Drug in Association with ... Dec 22, 2005
PharmaLive.com (press release), ...of Hyderabad, India. This product is the first generic version of the already approved Zerit for oral solution manufactured by Bristol-Myers Squibb. ...
Aurobindo Pharma Receives Tentative FDA Approval To Produce ... Dec 22, 2005
Kaiser network.org, Stavudine, manufactured by Bristol-Myers Squibb under the brand name Zerit, is used in combination with other antiretrovirals to treat HIV infection ( Kaiser ...
Generic HIV/AIDS Drug Wins Approval Dec 22, 2005
HealthCentral.com Relief. The drug, made by Aurobino Pharma Ltd. of India, is a generic version of the Bristol-Myers Squibb drug Zerit. The tentative ...
Aurobindo receives FDA approval for oral solution Dec 22, 2005
NewKerala.com, The company is also glad to share that, Stavudine oral solution one mg/ml is the first generic version approval of Zerit for oral solution manufactured by ...
FDA tentatively OK's generic anti-HIV drug Dec 22, 2005
The Advocate, The oral version of stavudine is the first generic version of the previously approved Zerit for oral solution manufactured by Bristol-Myers Squibb. ...
FDA Announces Tentative Approval for Pediatric Formulation of ... Dec 22, 2005
PharmaLive.com (press release), This product is the first generic version of the approved product, Zerit for oral solution, manufactured by Bristol-Myers Squibb. ...
- By Kishore Butani Dec 22, 2005
The Asian Age, Stavudine is the first generic version of the already approved Zerit for oral solution manufactured by Bristol-Myers Squibb and is in the class of drugs called ...
US FDA grants tentative approval to Aurobindo's anti-AIDS drug for ... Dec 23, 2005
domain-B, Stavudine Oral solution 1mg / ml is the first generic version approval of Zerit for oral solutions manufactured by Bristol-Myers Squibb. ...
FDA approves manufacture of AIDS drug by Hyderabad firm Dec 23, 2005
Webindia123, Hyderabad. This child friendly product Zerit, is indicated for use in pediatric patients with HIV, from birth through adolescence. ...
|
|
|
